| dc.contributor.author | Jyotirmoy Sarker | |
| dc.contributor.author | Michael Kim | |
| dc.contributor.author | Samantha Patton | |
| dc.contributor.author | Przemysław B. Radwański | |
| dc.contributor.author | Mark A. Munger | |
| dc.contributor.author | Kibum Kim | |
| dc.contributor.other | Department of Pharmacy Systems Outcomes and Policy, University of Illinois Chicago Chicago IL USA | |
| dc.contributor.other | Department of Pharmacy Systems Outcomes and Policy, University of Illinois Chicago Chicago IL USA | |
| dc.contributor.other | Department of Pharmacotherapy University of Utah Health Salt Lake City UT USA | |
| dc.contributor.other | Department of Physiology and Cell Biology The Ohio State University Columbus OH USA | |
| dc.contributor.other | Department of Pharmacotherapy University of Utah Health Salt Lake City UT USA | |
| dc.contributor.other | Department of Pharmacy Systems Outcomes and Policy, University of Illinois Chicago Chicago IL USA | |
| dc.date.accessioned | 2025-08-06T04:20:14Z | |
| dc.date.accessioned | 2025-10-08T08:28:07Z | |
| dc.date.available | 2025-10-08T08:28:07Z | |
| dc.date.issued | 01-08-2025 | |
| dc.identifier.uri | http://digilib.fisipol.ugm.ac.id/repo/handle/15717717/36037 | |
| dc.description.abstract | Background Icosapent ethyl (IPE) and omega‐3‐acid ethyl esters (docosahexaenoic acid [DHA]/eicosapentaenoic acid [EPA]) are approved as adjunct therapies to statins for reducing cardiovascular events in at‐risk patients. However, concerns remain regarding a potential link between IPE and atrial fibrillation (AF). We compared the risk of AF onset in patients who initiated IPE versus DHA/EPA as adjuncts to statin therapy. Methods We conducted a retrospective cohort study using the Merative MarketScan Commercial Claims and Medicare Supplemental database in the United States. An active‐comparator, new‐user study design was applied. Adults diagnosed with dyslipidemia and receiving statin therapy who initiated IPE or DHA/EPA between January 2013 and June 2021 were identified. A propensity score–matched cohort was created using baseline demographic characteristics, comorbidities, and medication dispensing records, with exact matching on therapy initiation period. Patients were followed for up to 2 years while they were on IPE or DHA/EPA therapy to identify incident AF. Cumulative incidence was estimated using Kaplan–Meier methods, and risks between groups were compared using Cox proportional hazards analysis. Results The propensity score–matched cohort included 17 635 participants, with a mean age of 55 years, and was predominantly men (65.4%). Over 2 years, the cumulative incidence of AF from IPE and DHA/EPA was 5.20% (95% CI, 4.62%–5.84%) and 4.07% (95% CI, 3.58%–4.62%) respectively, resulting in a hazard ratio of 1.21 (95% CI, 1.03–1.42). Conclusions These findings suggest that, in adult patients who are AF naïve, IPE may be associated with a higher risk of AF compared with DHA/EPA when used as add‐on therapy with statins. | |
| dc.language.iso | EN | |
| dc.publisher | Wiley | |
| dc.subject.lcc | Diseases of the circulatory (Cardiovascular) system | |
| dc.title | Comparative Risk of Atrial Fibrillation Onset in Statin‐Treated Patients Initiating Icosapent Ethyl and Omega‐3 Acid Ethyl Esters: A Retrospective Cohort Study | |
| dc.type | Article | |
| dc.description.keywords | atrial fibrillation | |
| dc.description.keywords | icosapent ethyl | |
| dc.description.keywords | omega‐3‐acid ethyl esters | |
| dc.description.keywords | retrospective cohort study | |
| dc.description.doi | 10.1161/JAHA.124.038846 | |
| dc.title.journal | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | |
| dc.identifier.e-issn | 2047-9980 | |
| dc.identifier.oai | bdfbc86449ef44e7ae26c4d212d259e7 | |
| dc.journal.info | Volume 14, Issue 15 | |
